K. To

ABCG2: determining its relevance in clinical drug resistance

S. Bates, R. Robey, O. Polgar, 2007, Cancer and Metastasis Reviews.

Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma.

H. Ng, M. Ng, K. Lo, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy

F. He, Yixiang Wang, Lingqiang Zhang, 2012, Nature Medicine.

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma

S. Steinberg, T. Fojo, S. Bates, 2010, British journal of haematology.

Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non‐functional variant transcript

J. Tong, J. Tong, M. Ng, 2003, British journal of haematology.